Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.

PMID:
29264697
2.

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP.

J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5.

3.

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.

PMID:
29052782
4.

The occhiolino (occ) mutant Zebrafish, a model for development of the optical function in the biological lens.

Aose M, Linbo TH, Lawrence O, Senoo T, Raible DW, Clark JI.

Dev Dyn. 2017 Nov;246(11):915-924. doi: 10.1002/dvdy.24511. Epub 2017 Jun 15.

PMID:
28422363
5.

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.

Atkins MB, Clark JI, Quinn DI.

Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151. Review.

PMID:
28383639
6.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

7.

Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

Klarquist J, Tobin K, Farhangi Oskuei P, Henning SW, Fernandez MF, Dellacecca ER, Navarro FC, Eby JM, Chatterjee S, Mehrotra S, Clark JI, Le Poole IC.

Cancer Res. 2016 Nov 1;76(21):6230-6240. Epub 2016 Sep 12.

8.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

9.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

10.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
11.

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face.

Block AM, Alite F, Diaz AZ, Borrowdale RW, Clark JI, Choi M.

Case Rep Oncol Med. 2015;2015:827608. doi: 10.1155/2015/827608. Epub 2015 Oct 4.

12.

Functional sequences in human alphaB crystallin.

Clark JI.

Biochim Biophys Acta. 2016 Jan;1860(1 Pt B):240-5. doi: 10.1016/j.bbagen.2015.08.014. Epub 2015 Sep 2. Review.

PMID:
26341790
13.

Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis: Implications for Targeted Therapy.

Jaber JJ, Murrill L, Clark JI, Johnson JT, Feustel PJ, Mehta V.

Otolaryngol Head Neck Surg. 2015 Aug;153(2):209-17. doi: 10.1177/0194599815581836. Epub 2015 Apr 27.

PMID:
25917669
14.

Multidisciplinary treatment of olfactory neuroblastoma: Patterns of failure and management of recurrence.

Petruzzelli GJ, Howell JB, Pederson A, Origitano TC, Byrne RW, Munoz L, Emami B, Clark JI.

Am J Otolaryngol. 2015 Jul-Aug;36(4):547-53. doi: 10.1016/j.amjoto.2015.02.008. Epub 2015 Feb 20.

PMID:
25749259
15.

A method to prevent protein delocalization in imaging mass spectrometry of non-adherent tissues: application to small vertebrate lens imaging.

Anderson DM, Floyd KA, Barnes S, Clark JM, Clark JI, Mchaourab H, Schey KL.

Anal Bioanal Chem. 2015 Mar;407(8):2311-20. doi: 10.1007/s00216-015-8489-5. Epub 2015 Feb 10.

16.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

17.

Genome sequencing of idiopathic pulmonary fibrosis in conjunction with a medical school human anatomy course.

Kumar A, Dougherty M, Findlay GM, Geisheker M, Klein J, Lazar J, Machkovech H, Resnick J, Resnick R, Salter AI, Talebi-Liasi F, Arakawa C, Baudin J, Bogaard A, Salesky R, Zhou Q, Smith K, Clark JI, Shendure J, Horwitz MS.

PLoS One. 2014 Sep 5;9(9):e106744. doi: 10.1371/journal.pone.0106744. eCollection 2014.

18.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.

Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI.

Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13.

19.

Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.

Malhotra B, Moon J, Kucuk O, Clark JI, Urba SG, Wolf GT, Worden FP.

Head Neck. 2014 Dec;36(12):1712-7. doi: 10.1002/hed.23522. Epub 2014 Jan 29.

20.

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

Dandamudi UB, Ghebremichael M, Sosman JA, Clark JI, McDermott DF, Atkins MB, Dutcher JP, Urba WJ, Regan MM, Puzanov I, Crocenzi TS, Curti BD, Vaishampayan UN, Crosby NA, Margolin KA, Ernstoff MS.

J Immunother. 2013 Nov-Dec;36(9):490-5. doi: 10.1097/CJI.0000000000000003.

PMID:
24145360
21.

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB.

Nat Rev Clin Oncol. 2013 Oct;10(10):588-98. doi: 10.1038/nrclinonc.2013.153. Epub 2013 Aug 27.

PMID:
23982524
22.

Self-assembly of protein aggregates in ageing disorders: the lens and cataract model.

Clark JI.

Philos Trans R Soc Lond B Biol Sci. 2013 Mar 25;368(1617):20120104. doi: 10.1098/rstb.2012.0104. Print 2013 May 5.

23.

Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.

Clark JI, Greene JB, Lau Clark A, Dalal JS, Hofmeister CC.

Med Oncol. 2013 Mar;30(1):358. doi: 10.1007/s12032-012-0358-x. Epub 2012 Dec 25.

PMID:
23266940
24.

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Gangadhar TC, Clark JI, Karrison T, Gajewski TF.

Invest New Drugs. 2013 Jun;31(3):769-73. doi: 10.1007/s10637-012-9897-4. Epub 2012 Nov 15.

25.

Tmod1 and CP49 synergize to control the fiber cell geometry, transparency, and mechanical stiffness of the mouse lens.

Gokhin DS, Nowak RB, Kim NE, Arnett EE, Chen AC, Sah RL, Clark JI, Fowler VM.

PLoS One. 2012;7(11):e48734. doi: 10.1371/journal.pone.0048734. Epub 2012 Nov 7.

26.

Hemoglobin interactions with αB crystallin: a direct test of sensitivity to protein instability.

Clark TJ, Houck SA, Clark JI.

PLoS One. 2012;7(7):e40486. doi: 10.1371/journal.pone.0040486. Epub 2012 Jul 18.

27.

New insights into the mechanism of lens development using zebra fish.

Greiling TM, Clark JI.

Int Rev Cell Mol Biol. 2012;296:1-61. doi: 10.1016/B978-0-12-394307-1.00001-1. Review.

PMID:
22559937
28.

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS.

Lancet Oncol. 2012 May;13(5):459-65. doi: 10.1016/S1470-2045(12)70090-6. Epub 2012 Mar 27.

PMID:
22456429
29.

Evolution of the vertebrate beaded filament protein, Bfsp2; comparing the in vitro assembly properties of a "tailed" zebrafish Bfsp2 to its "tailless" human orthologue.

Qu B, Landsbury A, Schönthaler HB, Dahm R, Liu Y, Clark JI, Prescott AR, Quinlan RA.

Exp Eye Res. 2012 Jan;94(1):192-202. doi: 10.1016/j.exer.2011.12.001. Epub 2011 Dec 11.

30.

Multiple sites in αB-crystallin modulate its interactions with desmin filaments assembled in vitro.

Houck SA, Landsbury A, Clark JI, Quinlan RA.

PLoS One. 2011;6(11):e25859. doi: 10.1371/journal.pone.0025859. Epub 2011 Nov 9.

31.

Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience.

Jaber JJ, Clark JI, Muzaffar K, Ruggiero FP, Feustel PJ, Frett MJ, Zender CA.

Head Neck. 2011 Jan;33(1):7-12. doi: 10.1002/hed.21403.

PMID:
20848424
32.

Dynamic subunit exchange and the regulation of microtubule assembly by the stress response protein human alphaB crystallin.

Houck SA, Clark JI.

PLoS One. 2010 Jul 26;5(7):e11795. doi: 10.1371/journal.pone.0011795.

33.

Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ.

N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

34.

Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.

Moncaster JA, Pineda R, Moir RD, Lu S, Burton MA, Ghosh JG, Ericsson M, Soscia SJ, Mocofanescu A, Folkerth RD, Robb RM, Kuszak JR, Clark JI, Tanzi RE, Hunter DG, Goldstein LE.

PLoS One. 2010 May 20;5(5):e10659. doi: 10.1371/journal.pone.0010659.

35.

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.

Gunturu KS, Meehan KR, Mackenzie TA, Crocenzi TS, McDermott D, Usherwood EJ, Margolin KA, Crosby NA, Atkins MB, Turk MJ, Ahonen C, Fuse S, Clark JI, Fisher JL, Noelle RJ, Ernstoff MS.

J Clin Oncol. 2010 Mar 1;28(7):1196-202. doi: 10.1200/JCO.2009.24.8153. Epub 2010 Feb 1.

36.

The zebrafish lens proteome during development and aging.

Greiling TM, Houck SA, Clark JI.

Mol Vis. 2009 Nov 13;15:2313-25.

37.

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.

Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK.

Cancer. 2010 Jan 15;116(2):424-31. doi: 10.1002/cncr.24739.

38.

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Gordon MS, Hussey M, Nagle RB, Lara PN Jr, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D.

J Clin Oncol. 2009 Dec 1;27(34):5788-93. doi: 10.1200/JCO.2008.18.8821. Epub 2009 Nov 2.

39.

Cell fate and differentiation of the developing ocular lens.

Greiling TM, Aose M, Clark JI.

Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1540-6. doi: 10.1167/iovs.09-4388. Epub 2009 Oct 15.

40.

A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.

Locke F, Clark JI, Gajewski TF.

Cancer Chemother Pharmacol. 2010 Feb;65(3):509-14. doi: 10.1007/s00280-009-1057-y. Epub 2009 Jul 12.

PMID:
19597729
41.

Early lens development in the zebrafish: a three-dimensional time-lapse analysis.

Greiling TM, Clark JI.

Dev Dyn. 2009 Sep;238(9):2254-65. doi: 10.1002/dvdy.21997.

42.

A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.

Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE.

Am J Clin Oncol. 2009 Oct;32(5):453-9.

43.

Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer.

Clark JI, Eisner RM, Hofmeister C, Norton J, Thomas S, Choudhury A, Petruzzelli G, Lathers D, Young MR, Lau A, Emami B.

Am J Clin Oncol. 2009 Aug;32(4):396-400. doi: 10.1097/COC.0b013e31818da9c7.

44.

Absence of SPARC leads to impaired lens circulation.

Greiling TM, Stone B, Clark JI.

Exp Eye Res. 2009 Sep;89(3):416-25. doi: 10.1016/j.exer.2009.04.008. Epub 2009 May 3.

45.

Clinicopathological review: esthesioneuroblastoma.

Bragg TM, Scianna J, Kassam A, Emami B, Brown HG, Hacein-Bey L, Clark JI, Muzaffar K, Boulis N, Prabhu VC.

Neurosurgery. 2009 Apr;64(4):764-70; discussion 770. doi: 10.1227/01.NEU.0000338948.47709.79. Review. No abstract available.

PMID:
19349835
46.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE.

Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7.

47.

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.

Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA.

Cancer. 2008 Oct 15;113(8):2139-45. doi: 10.1002/cncr.23805.

48.

Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation.

Levey SA, Bajwa RS, Picken MM, Clark JI, Barton K, Leehey DJ.

NDT Plus. 2008 Jun;1(3):154-6. doi: 10.1093/ndtplus/sfn013. Epub 2008 Mar 11. No abstract available.

49.

A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.

Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, Stadler WM.

Clin Genitourin Cancer. 2008 Mar;6(1):21-4. doi: 10.3816/CGC.2008.n.003.

50.

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS.

J Clin Oncol. 2008 May 10;26(14):2292-8. doi: 10.1200/JCO.2007.13.3165.

Supplemental Content

Loading ...
Support Center